Semaglutide reduces the risk of heart disease by improving cardiovascular outcomes and lowering the incidence of major cardiac events
The Science of the Half-Life To understand why weekly dosing is the standard, we have to look at the half-life of the medication
Patients on Semaglutide can develop gastroparesis where the stomach stops moving, and patients vomit considerably
For many, this wouldnt be a big deal
These represent mechanistically non-overlapping upstream (telomere) and downstream (oxidative damage) interventions in the ageing cascade, with distinct tissue specificities, experimental model requirements, and measurable endpoint panels
Over 9 weeks of step-up semaglutide dosing (from 0.25mg to 1.0mg weekly), participants showed sustained and dose-dependent reductions in nicotine craving